Search

Your search keyword '"Craxi, Antonio"' showing total 661 results

Search Constraints

Start Over You searched for: Author "Craxi, Antonio" Remove constraint Author: "Craxi, Antonio"
661 results on '"Craxi, Antonio"'

Search Results

1. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

2. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

3. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

4. A global research priority agenda to advance public health responses to fatty liver disease

5. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

6. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

8. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

14. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

15. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

16. Health Care at the Time of COVID-19

17. A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

19. FRI-405 Heterogeneity in the diagnostic performances of HDV-RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study

20. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort

21. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

22. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

24. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

25. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

26. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

27. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

31. Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease

37. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

38. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

39. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

43. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

45. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

46. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

47. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Catalog

Books, media, physical & digital resources